The oxazolidinones represent a novel chemical class of synthetic antimicrobial agents. DA-7218 (re-coded as TR-701 by Trius Therapeutics after in-licensing) is a second generation oxazolidinone antibacterial prodrug. It is a potent inhibitor of Gram-positive bacterial pathogens such as methicillin-resistant Staphylococccus aureus, penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant Enterococcus spp. DA-7218 is also active against pathogens that have developed resistance to first generation oxazolidinones such as linezolid-resistant S. aureus and linezolid-resistant Enterococcus spp. With a long half-life, high bioavailability and solubility and high potency, DA-7218 will provide clinicians with flexible dosing and a possible shorter course of therapy thereby enabling the early transition of hospitalized patients from IV to oral treatment and subsequent early discharge from the hospital. DA-7218 successfully completed Phase I and Phase II clinical trials in the US. In a recent Phase II clinical trail for treatment of complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria, DA-7218 was well tolerated and achieved high clinical cure rates in all doses evaluated. In this presentation, overall progress of the development of DA-7218 will be discussed.
한국생물공학회 [The Korean Society for Biotechnology and Bioengineering]
설립연도
1984
분야
공학>생물공학
소개
이 법인은 생물 공학의 발전과 보급에 이바지하고, 회원 상호 간의 연구 협력과 친목을 도모함을 목적으로 한다
1. 생물공학 분야의 발전을 위한 연구 협력
2. 생물공학의 실용화를 촉진시키기 위한 산학 협동
3. 학술연구 발표회, 강연회, 연수회 등 학술활동의 개최
4. 국,영문 학술지,소식지,학술회의 Proceedings 및 학술도서의 발간
5. 생물공학 발전을 위한 정책 건의
6. 기타 국제 교류 등 본 학회의 목적 달성을 위한 제반 활동